CPX-351 Therapy for MDS After Hypomethylating Agent Failure
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of treatment with CPX-351 (an FDA
approved drug for the treatment of AML) in individuals with MDS while using a new
stratification tool to predict outcomes of participants following HMA failure. This approach
is intended to gain a better understanding and insight into identifying new opportunities for
drug approvals in this setting.